PMID- 36551573
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 24
DP  - 2022 Dec 10
TI  - Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A 
      Nested Case-Control Study of 23 Million Individuals.
LID - 10.3390/cancers14246083 [doi]
LID - 6083
AB  - Background: Firm conclusions about whether long-term proton pump inhibitor (PPI) 
      drug use impacts female cancer risk remain controversial. Objective: We aimed to 
      investigate the associations between PPI use and female cancer risks. Methods: A 
      nationwide population-based, nested case-control study was conducted within 
      Taiwan's Health and Welfare Data Science Center's databases (2000-2016) and 
      linked to pathologically confirmed cancer data from the Taiwan Cancer Registry 
      (1979-2016). Individuals without any cancer diagnosis during the 17 years of the 
      study served as controls. Case and control patients were matched 1:4 based on 
      age, gender, and visit date. Conditional logistic regression with 95% confidence 
      intervals (CIs) was applied to investigate the association between PPI exposure 
      and female cancer risks by adjusting for potential confounders such as the 
      Charlson comorbidity index and medication usage (metformin, aspirin, and 
      statins). Results: A total of 233,173 female cancer cases were identified, 
      consisting of 135,437 diagnosed with breast cancer, 64,382 with cervical cancer, 
      19,580 with endometrial cancer, and 13,774 with ovarian cancer. After matching 
      each case with four controls, we included 932,692 control female patients. The 
      number of controls for patients with breast cancer, cervical cancer, endometrial 
      cancer, and ovarian cancer was 541,748, 257,528, 78,320, and 55,096, 
      respectively. The use of PPIs was significantly associated with reduced risk of 
      breast cancer and ovarian cancer in groups aged 20-39 years (adjusted odds ratio 
      (aOR): 0.69, 95%CI: 0.56-0.84; p < 0.001 and aOR: 0.58, 95%CI: 0.34-0.99; p < 
      0.05, respectively) and 40-64 years (aOR: 0.89, 95%CI: 0.86-0.94; p < 0.0001 and 
      aOR: 0.87, 95%CI: 0.75-0.99; p < 0.05, respectively). PPI exposure was associated 
      with a significant decrease in cervical and endometrial cancer risks in the group 
      aged 40-64 years (with aOR: 0.79, 95%CI: 0.73-0.86; p < 0.0001 and aOR: 0.72, 
      95%CI: 0.65-0.81; p < 0.0001, respectively). In contrast, in elderly women, PPI 
      use was found to be insignificantly associated with female cancers among users. 
      Conclusions: Our findings, based on real-world big data, can depict a 
      comprehensive overview of PPI usage and female cancer risk. Further clinical 
      studies are needed to elucidate the effects of PPIs on female cancers.
FAU - Nguyen, Nhi Thi Hong
AU  - Nguyen NTH
AD  - Health Personnel Training Institute, University of Medicine and Pharmacy, Hue 
      University, Hue 491-20, Vietnam.
AD  - School of Health Care Administration, College of Management, Taipei Medical 
      University, Taipei 11031, Taiwan.
FAU - Huang, Chih-Wei
AU  - Huang CW
AUID- ORCID: 0000-0002-2551-6199
AD  - International Center for Health Information Technology (ICHIT), College of 
      Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.
FAU - Wang, Ching-Huan
AU  - Wang CH
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 106339, Taiwan.
AD  - Biomedical Informatics & Data Science (BIDS) Section, School of Medicine, Johns 
      Hopkins University, 2024 E Monument St, Suite 1-200, Baltimore, MD 21205, USA.
FAU - Lin, Ming-Chin
AU  - Lin MC
AUID- ORCID: 0000-0001-9624-9705
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 106339, Taiwan.
AD  - Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, New 
      Taipei City 235041, Taiwan.
AD  - Taipei Neuroscience Institute, Taipei Medical University, Taipei 110301, Taiwan.
FAU - Hsu, Jason C
AU  - Hsu JC
AUID- ORCID: 0000-0003-2997-2404
AD  - Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei 
      106339, Taiwan.
AD  - Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei 
      110301, Taiwan.
AD  - Research Center of Health Care Industry Data Science, College of Management, 
      Taipei Medical University, Taipei 110301, Taiwan.
AD  - International Ph.D. Program in Biotech and Healthcare Management, College of 
      Management, Taipei Medical University, Taipei 110301, Taiwan.
FAU - Hsu, Min-Huei
AU  - Hsu MH
AD  - Office of Data Science, Taipei Medical University, Taipei 110301, Taiwan.
AD  - Graduate Institute of Data Science, College of Management, Taipei Medical 
      University, Taipei 110301, Taiwan.
FAU - Iqbal, Usman
AU  - Iqbal U
AD  - Health ICT, Department of Health, Hobart, TAS 700, Australia.
AD  - Global Health and Health Security Department, College of Public Health, Taipei 
      Medical University, Taipei 11031, Taiwan.
FAU - Nguyen, Phung-Anh
AU  - Nguyen PA
AUID- ORCID: 0000-0002-7436-9041
AD  - Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei 
      106339, Taiwan.
AD  - Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei 
      110301, Taiwan.
FAU - Yang, Hsuan-Chia
AU  - Yang HC
AUID- ORCID: 0000-0001-9198-0697
AD  - International Center for Health Information Technology (ICHIT), College of 
      Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 106339, Taiwan.
AD  - Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei 
      110301, Taiwan.
AD  - Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical 
      University, Taipei 116079, Taiwan.
LA  - eng
GR  - MOST 110-2320-B-038 -029 -MY3/Ministry of Science and Technology/
GR  - MOST 111-2321-B-038-004/Ministry of Science and Technology/
GR  - MOE DP2-111-21121-01-A-02/Higher Education Sprout Project by the Ministry of 
      Education/
PT  - Journal Article
DEP - 20221210
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9776228
OTO - NOTNLM
OT  - breast cancer
OT  - cancer risk
OT  - cervical cancer
OT  - endometrial cancer
OT  - ovarian cancer
OT  - proton pump inhibitor
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/10
CRDT- 2022/12/23 01:10
PHST- 2022/11/09 00:00 [received]
PHST- 2022/12/02 00:00 [revised]
PHST- 2022/12/08 00:00 [accepted]
PHST- 2022/12/23 01:10 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/10 00:00 [pmc-release]
AID - cancers14246083 [pii]
AID - cancers-14-06083 [pii]
AID - 10.3390/cancers14246083 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 10;14(24):6083. doi: 10.3390/cancers14246083.